0000899243-16-015241.txt : 20160303
0000899243-16-015241.hdr.sgml : 20160303
20160303214145
ACCESSION NUMBER: 0000899243-16-015241
CONFORMED SUBMISSION TYPE: 3
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20160222
FILED AS OF DATE: 20160303
DATE AS OF CHANGE: 20160303
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Unilife Corp
CENTRAL INDEX KEY: 0001476170
STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
IRS NUMBER: 271049354
STATE OF INCORPORATION: DE
FISCAL YEAR END: 0630
BUSINESS ADDRESS:
STREET 1: 250 CROSS FARM LANE
CITY: YORK
STATE: PA
ZIP: 17406
BUSINESS PHONE: (717) 384-3400
MAIL ADDRESS:
STREET 1: 250 CROSS FARM LANE
CITY: YORK
STATE: PA
ZIP: 17406
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AMGEN INC
CENTRAL INDEX KEY: 0000318154
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: 3
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34540
FILM NUMBER: 161483461
BUSINESS ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
BUSINESS PHONE: (805)447-1000
MAIL ADDRESS:
STREET 1: ONE AMGEN CENTER DRIVE
CITY: THOUSAND OAKS
STATE: CA
ZIP: 91320
FORMER NAME:
FORMER CONFORMED NAME: AMGEN
DATE OF NAME CHANGE: 19870305
3
1
doc3.xml
FORM 3 SUBMISSION
X0206
3
2016-02-22
0
0001476170
Unilife Corp
UNIS
0000318154
AMGEN INC
ONE AMGEN CENTER DRIVE
THOUSAND OAKS
CA
91320
0
0
1
0
6% Senior Secured Convertible Note due 2023
2016-02-22
2023-02-22
Common Stock
36108393
D
Includes shares issuable upon the conversion of interest accruable under the 6% Senior Secured Convertible Note due 2023 through maturity and payable through the addition of the amount of such interest to the then outstanding principal amount.
The 6% Senior Secured Convertible Note due 2023 is convertible into shares of the Issuer's Common Stock at any time prior to February 22, 2023, at a price per share that is 90% of the volume weighted average price of such shares during the twenty (20) trading days preceding the applicable conversion date, subject to a floor price of $1.25 per share (the "Conversion Rate Floor Price"). The Conversion Rate Floor Price is subject to customary adjustments for certain capital events.
Amgen Inc., by /s/ Andrea A. Robinson, Assistant Secretary and Associate General Counsel
2016-03-03